The study of how differences in metabolites in an individual or subset of the population might be used to predict their various responses to a medicine or medical intervention is known as pharmacometabolomics or pharmacometabonomics. The premise that an individual's metabolic profile is related to their health-to-disease status, referred to as their "metabotype," is at the centre of pharmacometabolomics. Pharmacometabolomics data can help understand different drug responses (i.e. responders vs non-responders), be used in precision medicine to determine drug dose levels or specific drugs to prescribe for an individual, provide biomarkers related to drug efficacy or toxicity effects, and, in many cases, provide pharmacokinetics information, making pharmacometabolomics useful for precision medicine. Pharmacometabolomics can be used to tailor treatment type, dose, and duration, as well as to track metabolite profiles during treatments. Existing '-omics' and health-record databases, as well as biobanks of human fluid samples and tissues, are valuable resources for pharmacometabolomics, which seeks to uncover biomarkers of therapeutic effects across the course of a disease.
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Personalized and precision medicine (PPM) can be established as a unique healthcare model through biodesign-driven and inspired biotech, translational applications. This approach aims to ensure human healthcare, wellness, and biosafety.
Sergey Suchkov, Institute for Biotech & Global Health of RosBioTech and A.I. Evdokimov MGMSU, Russian Federation
Title : Monitoring folds localization in ultra-thin transition metal dichalcogenides using optical harmonic generation
Ahmed Raza Khan, Australian National University, Australia
Title : A systematic review of regulatory approaches for Direct- To- Consumers (DTC) genetic testing
Kavitha Palaniappan, Duke-NUS Medical School, Singapore
Title : Regulatory framework of in vitro diagnostic and artificial intelligence for precision medicine
Pei Ting Sarah Chou, Regulatory Affairs Professionals Society, Taiwan
Title : Unraveling cancer stem cell signatures in circulating tumor cells of metastatic colorectal cancer: Investigating ALDH1A1 and the repurposing potential of disulfiram via scRNA-seq
Nurul Syakima Ab Mutalib, Universiti Kebangsaan Malaysia, Malaysia